- Home
- HSII vs AVXL Comparison
HSII vs AVXL Comparison
Compare HSII & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- AVXL
- Stock Information
- Founded
- HSII 1953
- AVXL 2004
- Country
- HSII United States
- AVXL United States
- Employees
- HSII N/A
- AVXL N/A
- Industry
- HSII Diversified Commercial Services
- AVXL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HSII Consumer Discretionary
- AVXL Health Care
- Exchange
- HSII Nasdaq
- AVXL Nasdaq
- Market Cap
- HSII 1.0B
- AVXL 956.7M
- IPO Year
- HSII 1999
- AVXL N/A
- Fundamental
- Price
- HSII $48.68
- AVXL $9.96
- Analyst Decision
- HSII Buy
- AVXL Strong Buy
- Analyst Count
- HSII 2
- AVXL 2
- Target Price
- HSII $51.00
- AVXL $44.00
- AVG Volume (30 Days)
- HSII 110.1K
- AVXL 1.2M
- Earning Date
- HSII 11-03-2025
- AVXL 08-12-2025
- Dividend Yield
- HSII 1.23%
- AVXL N/A
- EPS Growth
- HSII N/A
- AVXL N/A
- EPS
- HSII 1.60
- AVXL N/A
- Revenue
- HSII $1,155,576,000.00
- AVXL N/A
- Revenue This Year
- HSII $11.42
- AVXL N/A
- Revenue Next Year
- HSII $1.96
- AVXL N/A
- P/E Ratio
- HSII $30.36
- AVXL N/A
- Revenue Growth
- HSII 9.00
- AVXL N/A
- 52 Week Low
- HSII $36.49
- AVXL $5.03
- 52 Week High
- HSII $52.18
- AVXL $14.44
- Technical
- Relative Strength Index (RSI)
- HSII 44.48
- AVXL 61.28
- Support Level
- HSII $48.28
- AVXL $8.80
- Resistance Level
- HSII $50.83
- AVXL $8.92
- Average True Range (ATR)
- HSII 1.12
- AVXL 0.45
- MACD
- HSII -0.25
- AVXL 0.15
- Stochastic Oscillator
- HSII 12.78
- AVXL 95.35
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments include the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About AVXL Anavex Life Sciences Corp.
Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.